Therapeutic Use of Cytoprotective Agents in Canine and Feline Hepatobiliary Disease

Webster, Cynthia R. L.; Cooper, Johanna

doi:10.1016/j.cvsm.2009.02.002

Cited by 48 publications

(46 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[24][25][26][27] Ursodiol is also advocated in intra-and extrahepatic cholestasis in absence of complete bile duct obstruction. 28 Some of the known properties of ursodiol include: choleretic activity, antiapoptotic, and immunomodulatory properties. 28 Although used extensively in animal models of hepatotoxicity, little information is available on use of ursodiol in small animals.…”

Section: Discussionmentioning

confidence: 99%

“…28 Some of the known properties of ursodiol include: choleretic activity, antiapoptotic, and immunomodulatory properties. 28 Although used extensively in animal models of hepatotoxicity, little information is available on use of ursodiol in small animals. 6,29 There is some evidence both in vitro and in vivo that the actions of SAMe and ursodiol may be additive.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Findings and Prognostic Factors for Dogs Undergoing Cholecystectomy for Gall Bladder Mucocele

et al. 2013

View full text Add to dashboard Cite

Objective: To report clinical findings and explore prognostic factors for dogs that had cholecystectomy for gall bladder mucocele. Study Design: Retrospective case series. Animals: Dogs (n = 43) with gall bladder mucoceles. Results: Diagnosis of gall bladder mucoceles was confirmed by histopathology and 74% were diagnosed based on preoperative abdominal ultrasonography. Intraoperative evidence of gall bladder rupture was noted in 10 dogs (23%), and 16 (37%) had evidence of previous leakage in the abdominal cavity. One dog had positive bacterial growth from the gall bladder content. The most common histopathologic findings in liver biopsies obtained at surgery were cholangiohepatitis, biliary hyperplasia, or cholestasis. Univariate analysis showed evidence of postoperative hypotension (P = .05) to be significantly negatively associated with survival. Significant difference in mean postoperative serum lactate (P = .034) and postoperative packed cell volume (P = .063) between dogs that survived and died was also noted. Conclusions: Elevations in postoperative serum lactate concentrations and immediate postoperative hypotension in dogs undergoing cholecystectomy for gall bladder mucoceles are associated with poor clinical outcome.Although a recognized disease process for several decades, the incidence of gall bladder mucoceles (GM) in dogs appears to be increasing.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Clinical Findings and Prognostic Factors for Dogs Undergoing Cholecystectomy for Gall Bladder Mucocele

et al. 2013

View full text Add to dashboard Cite

show abstract

“…De nos jours, de nouvelles modalités thérapeutiques, les nutraceutiques 2 , sont préconisées à grand renfort de publicité pour diverses maladies telles que l'ostéoarthrite des animaux de compagnie et des équins et l'hépatite chronique des carnivores (Center 2004;Richardson & Loinaz, 2007;Webster & Cooper, 2009). Par définition, il s'agit de « substances qui, lorsqu'elles sont administrées oralement au patient exerceraient un effet bénéfique sur la santé et auraient la capacité de le protéger contre des maladies chroniques, par exemple ostéoarticulaires, cardiovasculaires, hépatiques » (Boothe, 2004).…”

Section: La Démarche De La Synthèse Méthodique Appliquée Aux Nutraceuunclassified

“…Par conséquent, en dépit de pouvoir être étiologique, le traitement se limite à une tentative d'amélioration des signes cliniques et de soutien aux capacités de réparation de l'organe (supportive therapy). (Center, 2004 ;Webster & Cooper, 2009). Ces synthèses sont exhaustives et référencient plus de 500 articles.…”

Section: Les Nutraceutiques Dans Le Traitement De L'hépatite Chroniquunclassified

La médecine factuelle, ou médecine fondée sur les preuves, appliquée aux nutraceutiques vétérinaires

Vandeweerd¹

2013

bavf

View full text Add to dashboard Cite

En médecine vétérinaire comme en médecine humaine, le praticien est amené à prendre des décisions diagnostiques, thérapeutiques ou préventives complexes. Le concept de la médecine fondée sur les preuves (evidence-based medicine ou EBM) est apparu pour la première fois au début des années 1990 en méde-cine humaine pour améliorer le processus de prise de décision, et consiste à intégrer de manière consciencieuse, explicite et judicieuse les meilleures preuves scientifiques (evidence) du moment dans la prise en charge du patient. Le concept fut introduit en médecine vétérinaire dans les pays anglo-saxons en 2003, et il a depuis été développé dans les pays francophones. Bien que des études récentes montrent que l'EBM ne peut être appliquée en médecine vétérinaire dans les mêmes termes qu'en médecine humaine, les praticiens vétérinaires sont tenus sur le plan éthique de prendre des décisions scientifiquement valides. La promotion de l'EBM en médecine vétérinaire requiert le développement d'outils adaptés, tels que des revues systématiques, ainsi que des améliorations spécifiques des études vétérinaires, avec en particulier l'enseignement d'une démarche de réflexion aux futurs praticiens. Le manque de preuves scientifiques de l'efficacité des nutraceutiques illustre à la fois les obstacles rencontrés pour la prise de décisions parfaitement informées et les faiblesses méthodologiques de la recherche en méde-cine vétérinaire. Mots

show abstract

“…The cytoprotective agents SAMe and ursodiol were used for their positive effects in necrotizing and inflammatory hepatopathies in dogs. Main beneficial mechanisms of action, among others, are indirect antioxidant properties of SAMe and choleretic qualities of ursodiol [13]. The authors acknowledge that it has not been proven that the dog's liver injury was caused by treatment with ZNS and only re-challenge could have provided this.…”

mentioning

confidence: 97%

Possible Drug-Induced Hepatopathy in a Dog Receiving Zonisamide Monotherapy for Treatment of Cryptogenic Epilepsy

Schwartz

Muñana

Olby

2011

The Journal of Veterinary Medical Science

View full text Add to dashboard Cite

ABSTRACT. A 9-year old female spayed Rottweiler was diagnosed with cryptogenic epilepsy and started on zonisamide monotherapy (8.3 mg/kg, PO, q 12 hr). Three weeks after the 1st dose of zonisamide the dog presented for vomiting, inappetence and icterus. Serum biochemistry showed marked elevation of liver enzymes, consistent with hepatocellular damage and cholestasis. No underlying cause for liver disease was identified and a drug-induced hepatopathy was suspected. Zonisamide was discontinued and replaced by potassium bromide. Supportive therapy consisted of intravenous fluids, antiemetics, antibiotics and hepatoprotectants. The dog made a complete recovery and serial serum biochemical examinations showed complete normalisation of liver parameters 8 weeks after discontinuation of zonisamide. Based on a human Drug-induced Liver Injury Diagnostic Scale, the likelihood for zonisamide-induced hepatopathy was classified as "possible". Veterinary practitioners and owners should be educated about the potential for an idiosyncratic drug reaction to zonisamide. If signs of hepatotoxicity are recognised early and zonisamide is discontinued, complete recovery is possible.KEY WORDS: antiepileptic drug, canine, idiosyncratic drug reaction, liver, seizure.J. Vet. Med. Sci. 73(11): 1505-1508, 2011 The sulfonamide derivate zonisamide (ZNS) is a new generation antiepileptic drug (AED) that was introduced into the Japanese market in 1989 and received licensure in the US and Europe in 2000 and 2005, respectively. While the US and European approval is limited to use as an add-on AED for humans with partial seizures, the Japanese license includes utilisation as mono-and adjunctive therapy for partial and generalised seizures [5].With blockage of voltage-sensitive sodium channels and T-type calcium channels, ZNS possesses a unique mode of action among the currently available AEDs. There is evidence that ZNS also exhibits direct effects on synthesis, release and degradation of the neurotransmitters glutamate, gamma aminobutyric acid (GABA), dopamine, serotonin and acetylcholine, thereby promoting synaptic inhibition. Furthermore, ZNS has been ascribed neuroprotective effects. To date it remains uncertain as to whether the direct effects on neurotransmitters and the neuroprotective properties play a role in the clinical use as an AED [1].In contrast to many of the newly developed anticonvulsants, ZNS has a sufficiently long serum elimination halflife in dogs, to allow maintenance of therapeutic blood levels by means of twice daily dosing [2,9]. This feature in particular has raised interest in using ZNS for treatment of canine epilepsy, and assessment of its use as add-on medication in cases of refractory epilepsy provided promising results with good rates of responders [3,11].Throughout the reports on the use of ZNS in dogs, the drug appears to have a favourable adverse effect profile. Side effects, including ataxia, lethargy and vomiting, were mild and transient and never warranted discontinuation [3,11]. A study on the chronic toxici...

show abstract

Therapeutic Use of Cytoprotective Agents in Canine and Feline Hepatobiliary Disease

Cited by 48 publications

References 76 publications

Clinical Findings and Prognostic Factors for Dogs Undergoing Cholecystectomy for Gall Bladder Mucocele

Clinical Findings and Prognostic Factors for Dogs Undergoing Cholecystectomy for Gall Bladder Mucocele

La médecine factuelle, ou médecine fondée sur les preuves, appliquée aux nutraceutiques vétérinaires

Possible Drug-Induced Hepatopathy in a Dog Receiving Zonisamide Monotherapy for Treatment of Cryptogenic Epilepsy

Contact Info

Product

Resources

About